All News #Library
Biotech
Sparingvision Completes PRODYGY Trial Patient Dosing With SPVN06,
09 Feb 2026 //
GLOBENEWSWIRE
Sparingvision Initiates First SPVN20 Dosing in Nyrvana Trial
28 Oct 2025 //
GLOBENEWSWIRE
SparingVision Reports +ve Initial Safety Data from the first cohort Ph I/II
30 Aug 2023 //
GLOBENEWSWIRE
SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics
12 Jul 2023 //
GLOBENEWSWIRE
SparingVision appoints Joseph C. Papa as Chairman
05 Apr 2023 //
GLOBENEWSWIRE

Market Place
Sourcing Support